Pembrolizumab

Healio spoke with Paolo Tarantino, MD, about treatments in the pipeline for metastatic breast cancer.

The combination of pembrolizumab and maintenance olaparib failed to significantly improve survival outcomes among adults with metastatic nonsquamous non-small cell lung cancer, according to the agent’s manufacturer.

SAN ANTONIO — Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting provided a durable EFS benefit for patients with early-stage triple-negative breast cancer, according to study results.

An analysis of global online conversations among health care professionals on social media in January showed celebration of the approval of a new drug for treatment of late-stage cervical cancer.

A regimen of pembrolizumab plus chemotherapy given before and after surgery induced a pathologic objective response in approximately 60% of patients with advanced gastric cancers, phase 2 study results published in JAMA Oncology showed.

Adjuvant therapy with pembrolizumab following nephrectomy conferred significant improvement in OS compared with placebo among adults with renal cell carcinoma who had a high risk for disease recurrence, study results showed.

Metabolic changes can be identified in patients with advanced melanoma by imaging tumors within 1 week of beginning immunotherapy, according to a study published in Clinical Cancer Research.

An analysis of online conversations among health care professionals on social media in December revealed collective enthusiasm following approval of the first two gene therapies for treatment of sickle cell disease.

This year’s San Antonio Breast Cancer Symposium featured several high-impact abstracts.

MADRID — Remarkable. Highly meaningful. Monumental.